RESUMEN
INTRODUCTION: The use of glucocorticosteroids (GCs) through oral, intravenous, intramuscular, or rectal routes is prohibited in sports. Its use is permitted through inhalation, topical and intra-articular route of administration. Methylprednisolone (MP) is available for use by different routes for anti-inflammatory and immunosuppressive purposes. To discriminate its intake by permitted & forbidden routes, a reporting level of 30 ng/ml is set by World Anti-Doping Agency. The aim of this study was to compare MP's excretion profile following oral & intra-articular administration & to evaluate its effect on endogenous GCs profile. MATERIALS & METHODS: The MP was administered through oral and intra-articular route to different patients & urine samples were collected up to 100 h. The urine samples were hydrolyzed, extracted, and analyzed on Liquid chromatography-mass spectrometry/MS. RESULTS: MP levels in urine exceeded the reporting limit of 30 ng/ml after oral (8 mg) and intra-articular administration (80 mg) routes. After oral intake (8 mg), MP levels exceeded the reporting level up to 24 h. However, after intra-articular injection (80 mg), the MP could be detected above the reporting level up to 80 h. CONCLUSION: The findings reveal that the MP can exceed the reporting level in urine even after administration by permitted route (i.a.). Further analysis of four endogenous GCs (Cortisol, Cortisone, TH Cortisone, and 11-deoxycortisol) showed a decreased excretion following administration of MP by oral & intra-articular routes.
Asunto(s)
Antiinflamatorios/farmacocinética , Metilprednisolona/farmacocinética , Administración Oral , Adulto , Antiinflamatorios/administración & dosificación , Antiinflamatorios/sangre , Doping en los Deportes , Humanos , Inyecciones Intraarticulares , Masculino , Metilprednisolona/administración & dosificación , Metilprednisolona/orina , UrinálisisRESUMEN
Methylprednisolone acetate (MPA) is commonly administered to performance horses, and therefore, establishing appropriate withdrawal times prior to performance is critical. The objectives of this study were to describe the plasma pharmacokinetics of MPA and time-related urine and synovial fluid concentrations following intra-articular administration to sixteen racing fit adult Thoroughbred horses. Horses received a single intra-articular administration of MPA (100 mg). Blood, urine, and synovial fluid samples were collected prior to and at various times up to 77 days postdrug administration and analyzed using tandem liquid chromatography-mass spectrometry (LC-MS/MS). Maximum measured plasma MPA concentrations were 6.06 ± 1.57 at 0.271 days (6.5 h; range: 5.0-7.92 h) and 6.27 ± 1.29 ng/mL at 0.276 days (6.6 h; range: 4.03-12.0 h) for horses that had synovial fluid collected (group 1) and those that did not (group 2), respectively. The plasma terminal half-life was 1.33 ± 0.80 and 0.843 ± 0.414 days for groups 1 and 2, respectively. MPA was undetectable by day 6.25 ± 2.12 (group 1) and 4.81 ± 2.56 (group 2) in plasma and day 17 (group 1) and 14 (group 2) in urine. MPA concentrations in synovial fluid remained above the limit of detection (LOD) for up to 77 days following intra-articular administration, suggesting that plasma and urine concentrations are not a good indicator of synovial fluid concentrations.
Asunto(s)
Antiinflamatorios/farmacocinética , Caballos/sangre , Caballos/orina , Metilprednisolona/análogos & derivados , Líquido Sinovial/química , Animales , Antiinflamatorios/sangre , Antiinflamatorios/orina , Femenino , Inyecciones Intraarticulares , Masculino , Metilprednisolona/sangre , Metilprednisolona/farmacocinética , Metilprednisolona/orina , Acetato de Metilprednisolona , Condicionamiento Físico AnimalRESUMEN
Methylprednisolone (MP) is prohibited in sports competitions when administered by systemic routes; however its use by topical administration is allowed. Therefore, analytical approaches to distinguish between these different administration pathways are required. A reporting level of 30ng/mL was established for this purpose. However, the suitability of that reporting level for MP is not known. In the present work, excretion profiles of MP and different metabolites after oral and topical administrations have been compared. A method for the quantification of MP and the qualitative detection of fifteen previously reported metabolites has been validated. The method involved an enzymatic hydrolysis, liquid-liquid extraction and analysis by liquid chromatography coupled to tandem mass spectrometry. The method was found to be linear, selective, precise and accurate. The high sensitivity (limit of detection 0.1ng/mL) and linear range (0.1-250ng/mL) achieved allowed for the quantification of MP at both the low concentrations present after topical administration and the high concentrations detected after oral intake. The method was applied to samples collected after oral (4 or 40mg) and topical administration (10mg of MP aceponate/day for 5 consecutive days) to healthy volunteers. After oral administration, MP and all metabolites were detected in urines collected up to at least 36h. Only MP and five metabolites were detected in samples obtained after topical treatment. As expected, concentrations of MP after topical administration were well below current reporting level (30ng/mL), however 3 out of 4 samples in range 8-24h after the low oral dose (4mg) were also below that concentration. Taking into account metabolites detected after both administration routes, metabolites 16ß,17α,21-trihydroxy-6α-methylpregna-1,4-diene-3,11,20-trione (M8) and 17α,20α,21-trihydroxy-6α-methylpregna-1,4-diene-3,11-dione (M11) are best markers to differentiate between topical and oral administrations. Their signals after topical administration were lower than those obtained in the first 48h after all oral doses.
Asunto(s)
Metilprednisolona/administración & dosificación , Metilprednisolona/orina , Administración Oral , Administración Tópica , Adulto , Cromatografía Liquida , Humanos , Masculino , Espectrometría de Masas , Metilprednisolona/farmacocinética , Adulto JovenRESUMEN
OBJECTIVE: To determine the pharmacokinetics of methylprednisolone (MP) and the relationship between MP and hydrocortisone (HYD) concentrations in plasma and urine after intra-articular (IA) administration of 100 or 200 mg of MP acetate (MPA) to horses. ANIMALS: Five 3-year-old Thoroughbred mares. PROCEDURES: Horses exercised on a treadmill 3 times/wk during the study. Horses received 100 mg of MPA IA, then 8 weeks later received 200 mg of MPA IA. Plasma and urine samples were obtained at various times for 8 weeks after horses received each dose of MPA; concentrations of MP and HYD were determined. Pharmacokinetic-pharmacodynamic estimates for noncompartmental and compartmental parameters were determined. RESULTS: Maximum concentration of MP in plasma was similar for each MPA dose; concentrations remained greater than the lower limit of quantitation for 18 and 7 days after IA administration of 200 and 100 mg of MPA, respectively. Maximum concentration and area under the observed concentration-time curve for MP in urine were significantly higher (approximately 10-and 17-fold, respectively) after administration of 200 versus 100 mg of MPA. Hydrocortisone concentration was below quantifiable limits for ≥ 48 hours in plasma and urine of all horses after administration of each MPA dose. CONCLUSIONS AND CLINICAL RELEVANCE: Pharmacokinetics of MP may differ among IA MPA dosing protocols, and MP may be detected in plasma and urine for a longer time than previously reported. This information may aid veterinarians treating sport horses. Further research is warranted to determine whether plasma HYD concentration can aid identification of horses that received exogenous glucocorticoids.
Asunto(s)
Antiinflamatorios/farmacocinética , Caballos/fisiología , Hidrocortisona/sangre , Metilprednisolona/análogos & derivados , Condicionamiento Físico Animal/fisiología , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/sangre , Antiinflamatorios/orina , Área Bajo la Curva , Femenino , Caballos/sangre , Caballos/orina , Hidrocortisona/metabolismo , Hidrocortisona/orina , Metilprednisolona/administración & dosificación , Metilprednisolona/sangre , Metilprednisolona/farmacocinética , Metilprednisolona/orina , Acetato de Metilprednisolona , Distribución Aleatoria , Tasa de Secreción/efectos de los fármacosRESUMEN
RATIONALE: The metabolism of methylprednisolone is revisited in order to find new metabolites that could be important for distinguishing between different routes of administration. Recently developed liquid chromatography/tandem mass spectrometry (LC/MS/MS) strategies for the detection of corticosteroid metabolites have been applied to the study of methylprednisolone metabolism. METHODS: The structures of these metabolites were studied using two complementary mass spectrometric techniques: LC/MS/MS in product ion scan mode with electrospray ionization and gas chromatography/mass spectrometry (GC/MS) in full scan mode with electron ionization. Metabolites were also isolated by semipreparative liquid chromatography fractionation. Each fraction was divided into two aliquots; one was studied by LC/MS/MS and the other by GC/MS after methoxyamine-trimethylsilyl derivatization. RESULTS: The combination of all the structural information allowed us to propose a comprehensive picture of methylprednisolone metabolism in humans. Overall, 15 metabolites including five previously unreported compounds have been detected. Specifically, 16ß,17α,21-trihydroxy-6α-methylpregna-1,4-diene-3,11,20-trione, 17α,20ß,21-trihydroxy-6α-methylpregna-1,4-diene-3, 11-dione, 11ß,17α,21-trihydroxy-6α-hydroxymethylpregna-1,4-diene-3,20-dione, 11ß,17α,20ξ,21-tetrahydroxy-6α-hydroxymethylpregna-1,4-diene-3-one, and 17α,21-dihydroxy-6α-hydroxymethylpregna-1,4-diene-3,11,20-trione are proposed as feasible structures for the novel metabolites. In addition to the expected biotransformations: reduction of the C20 carbonyl, oxidation of the C11 hydroxy group, and further 6ß-hydroxylation, we propose that hydroxylation of the 6α-methyl group can also take place. CONCLUSIONS: New metabolites have been identified in urine samples collected after oral administration of 40 mg of methylprednisolone. All identified metabolites were found in all samples collected up to 36 h after oral administration. However, after topical administration of 5 g of methylprednisolone aceponate, neither the parent compound nor any of the metabolites were detected.
Asunto(s)
Cromatografía de Gases y Espectrometría de Masas , Glucocorticoides/metabolismo , Glucocorticoides/orina , Metilprednisolona/metabolismo , Metilprednisolona/orina , Espectrometría de Masas en Tándem , Administración Oral , Administración Tópica , Cromatografía Liquida/métodos , Cromatografía de Gases y Espectrometría de Masas/métodos , Glucocorticoides/administración & dosificación , Humanos , Masculino , Metilprednisolona/administración & dosificación , Espectrometría de Masas en Tándem/métodosRESUMEN
A study on urinary metabolites of methylprednisolone acetate (MPA) has been performed by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) in precursor ion scanning (PIS) and neutral loss (NL) modes. Patients suffering from joint inflammation have been treated with Depo-Medrol® (MPA marketed suspension, 40 mg) intra-articularly (IA) and after a wash-out period, intramuscularly (IM) at the same dose. Urine samples have been collected after both the administration routes. Metabolites were identified in PIS mode by setting the fragment ion at m/z 161 which is specific for MPA, methylprednisolone (MP), methylprednisolone hemisuccinate, and in NL mode by selecting the losses of 54, 72, 176 and 194 Da. The MP-related structure of each target ion detected in both the MS modes was then confirmed by MS/MS acquisitions, and by accurate mass experiments. By using this approach, 13 MPA metabolites (M1-M13) have been identified, nine already reported in the literature and four unknown and for which the chemical structures have been proposed. No differences in the metabolic pattern of MPA when administered IM or IA were observed. The relative abundances of metabolites compared with the internal standard (MP-D2) were monitored by multiple reaction monitoring analysis for 19 days after both the administration routes.
Asunto(s)
Metilprednisolona/análogos & derivados , Adulto , Cromatografía Líquida de Alta Presión , Humanos , Inyecciones Intraarticulares , Inyecciones Intramusculares , Metilprednisolona/administración & dosificación , Metilprednisolona/orina , Acetato de Metilprednisolona , Persona de Mediana Edad , Osteoartritis/tratamiento farmacológico , Espectrometría de Masa por Ionización de Electrospray , Espectrofotometría Ultravioleta , Espectrometría de Masas en TándemRESUMEN
A new, simple, sensitive and specific liquid chromatography/electrospray ionization tandem mass spectrometric (LC/ESI-MS/MS) method in precursor ion scanning (PIS) mode has been developed for the rapid detection of methylprednisolone acetate (MPA) and its metabolites in rat urine. A suitable product ion specific for methylprednisolone (MP) and MPA was selected after a fragmentation study on 20 (cortico)steroids at different collision energies (5-40 eV). Urine samples were simply treated with acetonitrile then dried in a SpeedVac system. The method was validated and compared with other PIS methods for detecting corticosteroids in human urine. It was more sensitive, with limit of detection (LOD) and lower limit of quantitation (LLOQ), respectively, of 5 and 10 ng mL(-1). The method was applied for the analysis of rat urine collected before and after (24, 48, 72 h) intra-articular (IA) injection of a marketed formulation of MPA (Depo-Medrol(R)). MS/MS acquisitions were taken at different collision energies for the precursor ions of interest, detected in PIS mode, to verify the MP-related structure. Six different metabolites were detected in rat urine, and their chemical structures were assigned with a computational study.
Asunto(s)
Metilprednisolona/análogos & derivados , Espectrometría de Masa por Ionización de Electrospray/métodos , Espectrometría de Masas en Tándem/métodos , Animales , Humanos , Masculino , Metilprednisolona/química , Metilprednisolona/metabolismo , Metilprednisolona/orina , Acetato de Metilprednisolona , Estructura Molecular , Ratas , Ratas Wistar , Sensibilidad y EspecificidadRESUMEN
Different approaches for the non-target detection of corticosteroids in urine have been evaluated. As a result of previous studies about the ionization (positive/negative) and fragmentation of corticosteroids, several methods based on both precursor ion (PI) and neutral loss (NL) scans are proposed. The applicability of these methods was checked by the injection of a standard solution containing 19 model compounds. Five of the studied methods (NL of 76 Da; PI of 77, 91 and 105; PI of 237; PI of 121, 147 and 171; and NL of 38 Da) exhibited satisfactory results at the concentration level checked (corresponding to 20 ng/ml in sample). Some other methods in negative ionization mode such as the NL of 104 Da were found to lack sufficient sensitivity. Some of the applied methods were found to be specific for a concrete structure (NL of 38 Da for fluorine containing corticosteroids) while others showed a wide range applicability (PI of 77, 91 and 105 showed response in all model compounds). Interference by endogenous compounds was also tested by the analysis of negative urines and urines spiked with different corticosteroids. The suitability of these methods for the detection of corticosteroid metabolites was checked by the analysis of urine samples collected after the administration of methylprednisolone and triamcinolone. A combination of the reported methods seems to be the approach of choice in order to have a global overview about the excreted corticosteroid metabolites.
Asunto(s)
Corticoesteroides/metabolismo , Corticoesteroides/orina , Cromatografía Liquida/métodos , Espectrometría de Masas en Tándem/métodos , Adulto , Humanos , Masculino , Metilprednisolona/administración & dosificación , Metilprednisolona/orina , Sensibilidad y Especificidad , Triamcinolona/administración & dosificación , Triamcinolona/orina , Adulto JovenRESUMEN
Electrochemical behaviour of methylprednisolone (MP) at the fullerene-C60-modified glassy carbon electrode has been investigated using differential pulse voltammetry. The experimental results suggest that the modified electrode exhibits electrocatalytic effect on the oxidation of MP resulting in a marked enhancement of the peak current response. Under the selected conditions, the oxidation peak current was linearly dependent on the concentration of MP in the range 5.0 nM-1.0 microM with a sensitivity of 0.0107 microA microM(-1). The detection limit was estimated to be 5.6 nM. The electrode showed good sensitivity, selectivity, stability and reproducibility. In addition, the developed method was satisfactorily applied to the determination of MP in pharmaceutical formulations and human serum and urine samples without any necessity for sample treatment or time-consuming extraction steps prior to the analysis. GC-MS method was used to cross-validate the results obtained for the quantitative estimation of MP in biological fluids and the results showed approximately 2% deviation to those obtained using the proposed method.
Asunto(s)
Metilprednisolona/sangre , Metilprednisolona/orina , Preparaciones Farmacéuticas/química , Electroquímica , Humanos , Metilprednisolona/análisis , Estructura Molecular , Sensibilidad y Especificidad , Factores de TiempoRESUMEN
The electrochemical behavior of a corticosteroid methylprednisolone (MP), used for doping, has been studied at gold nanoparticles modified indium tin oxide (nanoAu/ITO) electrode. The nanoAu/ITO electrode exhibited an effective catalytic response towards its oxidation and lowered its oxidation potential by approximately 127 mV when compared with bare ITO electrode. Oxidation of MP has been carried out in phosphate containing electrolyte in the pH range 2.13-10.00 and a well-defined oxidation peak was noticed. Linear concentration curves are obtained over the concentration range 0.01-1.0 microM with a detection limit of 2.68 x 10(-7)M at nanoAu/ITO electrode. A diffusion coefficient of 2.36 x 10(-6)cm(2)/s is calculated for MP using chronoamperometry. The proposed method is effectively applied to detect the concentration of MP in pharmaceutical formulations and human blood plasma and urine samples. A comparison of MP concentration determined in blood plasma and urine by the proposed method and GC/MS indicated that the results are essentially similar. It is believed that the method will be useful in determining this drug in case of doping.
Asunto(s)
Glucocorticoides/sangre , Glucocorticoides/orina , Oro/química , Metilprednisolona/sangre , Metilprednisolona/orina , Nanopartículas/química , Electroquímica/métodos , Electrodos , Glucocorticoides/química , Humanos , Concentración de Iones de Hidrógeno , Indio/química , Metilprednisolona/química , Estructura Molecular , Nanopartículas/ultraestructura , Oxidación-Reducción , Tamaño de la Partícula , Fosfatos/química , Compuestos de Estaño/químicaRESUMEN
Cortisol is an important adrenal steroid hormone involved in the regulation of metabolic homeostasis. A new liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) multiple reactant monitoring (MRM) procedure for the measurement of cortisol concentration in plasma ultrafiltrate, whole plasma, and urine was developed and validated. Plasma, plasma ultrafiltrate, or urine was extracted by ethyl acetate. The extract was subjected to liquid chromatography with an Inertsil ODS-3 column with an aqueous NH4Cl (1 mM, pH 9.0):methanol mobile phase. The presence of NH4Cl in the mobile phase induced the formation of [M+Cl] in the first quadrupole at m/z 397 and 409 for cortisol and 6alpha-methylprednisolone (internal standard), respectively. In the collision cell, the complex dissociated to the neutral parent and the chloride ion at m/z 35; the latter ion was used for quantification. The calibration curve was linear from 0.5 to 100 ng/mL. The lower limit of quantification was 0.50 ng/mL and the limit of detection was 0.25 ng/mL. For quality control samples prepared in water, the intrabatch assay precision was 5.6%, 9.6%, and 9.9% at 50, 10, and 1 ng/mL, respectively. The interbatch assay precision was 4.2%, 6.3%, and 7.5% at 50, 10, and 1 ng/mL, respectively. For measurement of endogenous cortisol in plasma and urine samples, the intra-assay and interassay precision was 10.8% and 4.8% for total plasma cortisol, 13.1% and 5.2% for free plasma cortisol, 10.9% and 13.1% for cortisol protein-binding free fraction, and 8.9% and 14.4% for urine cortisol, respectively. A simple procedure of ultrafiltration coupled with the highly sensitive LC-MS/MS quantification offered a rapid and reproducible assay for plasma free cortisol, which may be useful in the assessment of adrenal function in patients, especially critically ill patients with abnormal protein binding. It may also be useful for plasma and urinary cortisol measurements in pharmacodynamic studies of adrenocorticoid response.
Asunto(s)
Hidrocortisona/sangre , Hidrocortisona/orina , Adolescente , Adulto , Proteínas Sanguíneas/metabolismo , Cromatografía Liquida , Femenino , Humanos , Masculino , Metilprednisolona/sangre , Metilprednisolona/orina , Persona de Mediana Edad , Unión Proteica , Sensibilidad y Especificidad , Espectrometría de Masa por Ionización de Electrospray , Espectrometría de Masas en TándemRESUMEN
A liquid chromatography-mass spectrometry (LC-MS) method for the analysis of corticosteroids in equine urine was developed. Corticosteroid conjugates were hydrolysed with beta-glucuronidase; free and enzyme-released corticosteroids were then extracted from the samples with ethyl acetate followed by a base wash. The isolated corticosteroids were detected by LC-MS and confirmed by LC-MS-MS in the positive atmospheric pressure chemical ionisation mode. Twenty-three corticosteroids (comprising hydrocortisone, deoxycorticosterone and 21 synthetic corticosteroids), each at 5 ng/ml in urine, could easily be analysed in 10 min.
Asunto(s)
Corticoesteroides/orina , Antiinflamatorios/orina , Cromatografía Liquida/métodos , Caballos/orina , Corticoesteroides/administración & dosificación , Animales , Dexametasona/administración & dosificación , Dexametasona/orina , Glucuronidasa , Hidrocortisona/orina , Espectrometría de Masas , Metilprednisolona/administración & dosificación , Metilprednisolona/orina , Reproducibilidad de los Resultados , Triamcinolona Acetonida/administración & dosificación , Triamcinolona Acetonida/orinaRESUMEN
Fourteen metabolites of methylprednisolone have been analysed by gradient-elution high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS). The compounds were separated on a Cp Spherisorb 5 microm ODS column connected to a guard column packed with pellicular reversed phase. The mobile phase was an acetonitrile- 1.0% aqueous acetic acid gradient at a flow rate of 1.5 mL min(-1) The analysis gave a complete picture of parent drug, prodrugs and metabolites, and the alpha/beta stereochemistry was resolved. The short (1-2 h) elimination half-life of methylprednisolone is explained by extensive metabolism. The overall picture of the metabolic pathways of methylprednisolone is apparently simple-reduction of the C20 carbonyl group and further oxidation of the C20,C21 side chain (into C21COOH and C20COOH), in competition with or in addition to oxidation at the C6 position.
Asunto(s)
Antiinflamatorios/metabolismo , Metilprednisolona/metabolismo , Profármacos/metabolismo , Antiinflamatorios/administración & dosificación , Antiinflamatorios/orina , Cromatografía Líquida de Alta Presión/métodos , Glucuronatos/metabolismo , Humanos , Espectrometría de Masas/métodos , Metilprednisolona/administración & dosificación , Metilprednisolona/orina , Hemisuccinato de Metilprednisolona/administración & dosificación , Hemisuccinato de Metilprednisolona/metabolismo , Hemisuccinato de Metilprednisolona/orina , Oxidación-Reducción , Estereoisomerismo , Agua/químicaRESUMEN
In the present study metabolites of methylprednisolone were detected using gradient elution high-performance liquid chromatography. Separation was performed by a Cp Spherisorb ODS 5 microm (250 mmx4.6 mm I.D.) column, connected to a guard column, packed with pellicular reversed phase. The mobile phase was a mixture of acetonitrile and 1% acetic acid in water. At t = 0, this phase consisted of 2% acetonitrile and 98% acetic acid 1% in water (v/v). During the following 35 min the phase changed linearly until it attained a composition of acetonitrile-buffer (50:50, v/v). At 40 min (t = 40) the mobile phase was changed over 5 min to the initial composition, followed by equilibration during 2 min. The flow-rate was 1.5 ml/min. UV detection was achieved at 248 nm. We have isolated the respective compounds with the most abundant concentration and suggested their chemical structure based on NMR, IR, UV, MS, retention behaviour and melting points. The c/, stereochemistry could not be solved in this study. The overall picture of the metabolic pathways of methylprednisolone is apparently simple: reduction of the C20 carbonyl group and further oxidation of the C20-C21 side chain (into C21-COOH and C20-COOH), in competition with or additional to the oxidation at the C6-position.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Metilprednisolona/orina , Humanos , Metilprednisolona/administración & dosificación , Metilprednisolona/metabolismo , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/orina , Análisis EspectralRESUMEN
We here report a reversed-phase HPLC method for the determination of free cortisol in human urine, using methylprednisolone as the internal standard. Before chromatography, samples were extracted with a C18 solid-phase extraction column and the steroids were separated on a LiChrospher 100 C18 column with a mobile phase of methanol/acetonitrile/water (43/3/54 by vol). Linearity, precision, and accuracy of the method were established. The detection limit was 10 pmol of cortisol, and total CVs were < 8%. With various solid-phase extraction columns the recovery of cortisol was 36-97%; recovery of the internal standard was 43-85%. Study of interference by 6 other steroids and metabolites and 24 drugs showed that carbamazepine and digoxin partly overlapped with cortisol, but this interference could be reduced by modification of the mobile phase. The HPLC method was compared with an RIA and an automated immunoassay method. The results obtained by HPLC averaged 40% of the RIA values.
Asunto(s)
Cromatografía Líquida de Alta Presión , Hidrocortisona/orina , Calibración , Carbamazepina/orina , Síndrome de Cushing/orina , Digoxina/orina , Humanos , Inmunoensayo , Metilprednisolona/orina , Radioinmunoensayo , Valores de Referencia , Análisis de Regresión , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Esteroides/orinaRESUMEN
AIMS: The aim of this study was to establish whether pharmacokinetic differences between two pro-drugs of methylprednisolone (MP) are likely to be of clinical significance. METHODS: This study was a single-blind, randomized, crossover design comparing the bioequivalence of MP released from the pro-drugs Promedrol (MP suleptanate) and Solu-Medrol (MP succinate) after a single 250 mg (MP equivalent) intramuscular injection to 20 healthy male volunteers. Bioequivalence was assessed by conventional pharmacokinetic analysis, by measuring pharmacodynamic responses plus a novel approach using pharmacokinetic/pharmacodynamic modeling. The main measure of pharmacodynamic response was whole blood histamine (WBH), a measure of basophil numbers. RESULTS: The MP Cmax was less for MP suleptanate due to a longer absorption halflife of the prodrug from the intramuscular injection site. The bioavailability of MP was equivalent when based on AUC with a MP suleptanate median 108% of the MP succinate value (90% CI: 102-114%). For Cmax the MP suleptanate median was 81% of the MP succinate value (90% CI: 75-88%). The tmax for MP from MP suleptanate was delayed relative to MP succinate. The median difference was 200% (90% non-parametric CI: 141-283%). The area under the WBH effect-time curve (AUEC) and the maximum response (Emax) were found to be equivalent (90% CI: 98-113% and 93-109% respectively). The maximum changes in other white blood cell counts, blood glucose concentration and the parameters of the pharmacodynamic sigmoid Emax model (EC50, Emax and gamma) were also not significantly different between prodrugs. CONCLUSIONS: MP suleptanate is an acceptable pharmaceutical alternative to MP succinate. The use of both pharmacokinetic and pharmacodynamic response data together gives greater confidence in the conclusions compared with those based only on conventional pharmacokinetic bioequivalence analysis.
Asunto(s)
Glucocorticoides/farmacocinética , Histamina/sangre , Hemisuccinato de Metilprednisolona/farmacocinética , Metilprednisolona/análogos & derivados , Profármacos/farmacocinética , Adolescente , Adulto , Análisis de Varianza , Área Bajo la Curva , Basófilos/citología , Basófilos/efectos de los fármacos , Disponibilidad Biológica , Glucemia/metabolismo , Cromatografía Líquida de Alta Presión , Estudios Cruzados , Glucocorticoides/sangre , Glucocorticoides/farmacología , Glucocorticoides/orina , Humanos , Recuento de Leucocitos/efectos de los fármacos , Masculino , Metilprednisolona/sangre , Metilprednisolona/farmacocinética , Metilprednisolona/farmacología , Metilprednisolona/orina , Hemisuccinato de Metilprednisolona/análisis , Hemisuccinato de Metilprednisolona/farmacología , Persona de Mediana Edad , Profármacos/análisis , Profármacos/farmacología , Radioinmunoensayo , Método Simple Ciego , Equivalencia TerapéuticaAsunto(s)
Cromatografía Líquida de Alta Presión/métodos , Cortodoxona/análisis , Dexametasona/análisis , Hidrocortisona/análisis , Metilprednisolona/análisis , Prednisolona/análisis , Adolescente , Adulto , Cromatografía Líquida de Alta Presión/estadística & datos numéricos , Cortodoxona/sangre , Cortodoxona/orina , Dexametasona/sangre , Dexametasona/orina , Femenino , Humanos , Hidrocortisona/sangre , Hidrocortisona/orina , Masculino , Metilprednisolona/sangre , Metilprednisolona/orina , Persona de Mediana Edad , Prednisolona/sangre , Prednisolona/orina , Valores de Referencia , Sensibilidad y EspecificidadRESUMEN
A reversed-phase high-performance liquid chromatography (HPLC) method for the simultaneous determination of cortisol and cortisone in human urine samples using methylprednisolone as the internal standard is described. The method involves the systematic use of isocratic mobile phases of water and methanol, acetonitrile or tetrahydrofuran and a reversed-phase Hypersil C18 column. A water-acetonitrile mixture used as the mobile phase proved to be the most adequate one for analyzing urine samples purified by solvent extraction. The proposed method is sensitive, reproducible and selective. It was applied to the determination of cortisol and cortisone in several human urine samples: healthy subjects, sportsmen before and/or after stress for doping control purposes, and patients with Cushing's syndrome.
Asunto(s)
Cromatografía Líquida de Alta Presión , Cortisona/orina , Hidrocortisona/orina , Calibración , Cortisona/análisis , Síndrome de Cushing/orina , Doping en los Deportes , Humanos , Hidrocortisona/análisis , Modelos Lineales , Metilprednisolona/orina , Estructura Molecular , Estándares de Referencia , Valores de Referencia , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Solventes , DeportesRESUMEN
The disposition of methylprednisolone (MP) and its prodrug hemisuccinate (MPHS) was assessed in six middle-aged patients with chronic liver disease (CLD) and compared with six younger, healthy subjects after a single IV dose of 25.4 mg of MPHS. Blood and urine samples were collected over 12 hours. Plasma and urine concentrations of MPHS and MP and plasma cortisol were measured by HPLC. MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ. The elimination half-life, t1/2 beta, was significantly longer in CLD (0.61 vs. 0.32 hr). The percent recovery of unchanged MPHS in urine was similar (about 9%) in both groups. The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr). The suppression t1/2 of cortisol after MPHS was longer (3.9 vs. 1.9 hr) indicating metabolic pathways for cortisol and MP are affected differently in CLD. Reduction in MPHS CL may reflect altered hepatic blood flow due to both cirrhosis and age effects. However, good availability of MP from MPHS and lack of perturbation of MP pharmacokinetics in CLD patients may provide therapeutic advantages in selection of this glucocorticoid. This is the first study that characterizes the disposition of the prodrug MPHS and the formation of MP simultaneously in CLD patients.
Asunto(s)
Cirrosis Hepática Alcohólica/metabolismo , Hemisuccinato de Metilprednisolona/farmacocinética , Metilprednisolona/farmacocinética , Adulto , Enfermedad Crónica , Semivida , Humanos , Hidrocortisona/sangre , Hipertensión Portal/metabolismo , Cirrosis Hepática Alcohólica/enzimología , Masculino , Metilprednisolona/sangre , Metilprednisolona/orina , Hemisuccinato de Metilprednisolona/sangre , Hemisuccinato de Metilprednisolona/orina , Persona de Mediana EdadRESUMEN
A reversed-phase high-performance liquid chromatographic (RP-HPLC) method for the measurement of methylprednisolone hemisuccinate (MPHS) and its metabolites methylprednisolone (MP), 20-alpha- (20a-HMP), and 20-beta-hydroxymethylprednisolone (20b-HMP) in urine is described. The metabolites were extracted from urine samples using Extrelut columns and eluted with ethylacetate. The mobile phase for RP-HPLC comprised methanol:citrate buffer:tetrahydrofuran (30:65:5, vol/vol/vol) with UV detection at 251 nm. Fractions were collected, pooled and the metabolites present were identified by gas chromatography-mass spectrometry and normal-phase HPLC (NP-HPLC). By RP-HPLC 30 +/- 7.3% (mean +/- 1 SD) of the dose was detected in the 0-24 h urine sample following a 1 g MPHS infusion to patients with rheumatoid arthritis; MPHS contributed 9.9 +/- 5.0%, MP 12.1 +/- 2.9%, 20a-HMP 7.8 +/- 2.2%, and 20b-HMP 1.0 +/- 0.3%, respectively. A further 1.0 +/- 0.9% of the administered dose was detected in urine collected 24-48 h postinfusion.